Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study.
Lymphoma survivors in the modern treatment era have quantifiable risks for secondary cancers, enabling tailored long-term monitoring strategies.
Lymphoma patients treated in the modern targeted therapy era carry a quantifiable secondary primary malignancy risk with characterised survival impacts, informing long-term survivorship surveillance protocols. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Blood and Lymphatic Cancer: Targets and Therapy
Why it surfaced
Clinically relevant secondary malignancy risk quantification in lymphoma; important for long-term survivorship monitoring in the modern therapy era.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.